Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

The conclusion of the conversation is that some individuals may experience a condition called reactionary hypergonadism when taking dutasteride for hair loss. This condition can lead to an increase in testosterone levels, which may worsen hair loss instead of improving it.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

Dutasteride is more effective than finasteride for hair loss, with some users experiencing fewer side effects. Users share experiences with dutasteride, finasteride, minoxidil, and biotin, discussing dosage and fertility concerns.

A user plans to switch from finasteride to dutasteride for better hair loss treatment, citing dutasteride's higher DHT suppression. Others share mixed experiences, discussing transition methods, shedding, and potential side effects.

Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.

A user experienced worsening hair recession after adding 0.5 mg daily dutasteride to their regimen of topical minoxidil and finasteride, despite no initial shedding. They plan to continue monitoring the situation, as others suggest it may be too early to see results and recommend blood tests to check DHT levels.

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

The conversation discusses concerns about using Ashwagandha with Dutasteride for hair loss, as Ashwagandha may increase testosterone and potentially affect DHT levels. Users generally agree that the increase in DHT is minimal and unlikely to impact the effectiveness of Dutasteride significantly.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

A user on .5 mg of dutasteride for hair loss saw no improvement and is considering increasing to 2.5 mg but is unsure of its effectiveness. Another user mentioned that 2.5 mg reduces scalp DHT more and increases hair count more than .5 mg, but the cost and side effects should be considered.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.

Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.

Using Dutasteride as a hair loss treatment and its potential benefits, including availability in certain countries without a prescription and lower side effects than Minoxidil or RU58841.

The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.

The conversation is about choosing an additional topical treatment for hair loss, with options being fluridil, topical spiro, or alfatradiol, alongside existing treatments like dutasteride, oral minoxidil, latanoprost, and RU58841. Opinions vary on the effectiveness of adding these topicals, with some suggesting RU58841 is sufficient.